Zebrafish Drug Screening Identifies Erlotinib as an Inhibitor of Wnt/β-Catenin Signaling and Self-Renewal in T-cell Acute Lymphoblastic Leukemia.
Majd A Al-HamalyAnna H CoxMeghan G HaneyWen ZhangEmma C ArvinShilpa SampathiMary WimsettChunming LiuJessica S BlackburnPublished in: bioRxiv : the preprint server for biology (2023)
. Erlotinib, an Epidermal Growth Factor Receptor (EGFR) inhibitor, emerged as a potent and promising Wnt inhibitor with effects in both zebrafish and human cell-based Wnt reporter assays.The identification of Erlotinib as a Wnt inhibitor underscores the value of repurposed drugs in developing targeted therapies to disrupt cancer stemness and improve clinical outcomes.
Keyphrases
- epidermal growth factor receptor
- advanced non small cell lung cancer
- stem cells
- tyrosine kinase
- cell proliferation
- acute lymphoblastic leukemia
- endothelial cells
- small cell lung cancer
- single cell
- epithelial mesenchymal transition
- genome wide
- crispr cas
- high throughput
- papillary thyroid
- gene expression
- adverse drug
- childhood cancer
- squamous cell